Schering sells Jenapharm's therapeutics business to Dermapharm AG
Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that its German subsidiary Jenapharm GmbH & Co. KG, Jena, has agreed the sale of its therapeutics business to mibe Vertriebsgesellschaft mbH (i.G.), Jena, a subsidiary of Dermapharm AG, Grünwald.
The sale of Jenapharm GmbH & Co. KG's largely generic therapeutics business is part of the Schering Group's strategic focus program. The transaction, whereby more than 80 Jenapharm employees will be taken on by mibe Vertriebsgesellschaft mbH (i.G.), Jena, should be completed by October 1, 2004. Jenapharm's therapeutics business generated net sales of EUR 38 million in 2003. Financial details of the transaction were not disclosed.
Jenapharm's therapeutics business includes systemic corticoids, inhalative anti-asthmathics and medicines for treating osteoporosis and further indications. Products included are, for example, Prednisolut®, Hydrocortison®, Calcilac®, Prednisolon® and Aescusan®. The complete product range comprises approximately 65 products.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.